Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See more on FBIO.
FDLO ETF review: low-volatility factor exposure, 2026 performance vs. IVV/SPLV/USMV, and why weak upside capture may lag the market. See more here.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果